Pathology of white cell disorders II - Zaloga Flashcards
precursor B and T cell neoplasms
- immature big blast cells
- usually leukemia, sometimes lymphoma
peripheral B and T cell neoplasm
- mature cells that go to secondary lymphoid organ
- usually lymphoma
Hodgkin lymphoma
-Reed-sternburg cells*** and variant cells
lymphoid neoplasm
- from B or T cell differentiation
- antigen receptor genes/proteins distinguish between reactive (polyclonal) and malignant (monoclonal) tumors
what can plasma cells lead to?
multiple myeloma
what are surface markers used for?**
- recognized by antibodies to distinguish between lymphomas and leukemias
- B cells: markers CD10,19,20,21,23,79a
- T cells: markers CD1-8
- Monocyte/macrophage: markers CD11c,13,14,15,33,64
- NK: markers CD16,56
- HSC: marker CD34
- marker on all leukocytes: CD45
Acute lymphoblastic leukemia
- most common cancer in children**
- B-ALL (most common; in child) and T-ALL (adolescence; thymic lymphoma) –> tDt present in both**
- good regression with chemo
- t(12;21) –> good prognosis**
- antibody test to differentiate from AML
- hypercellular marrow packed with lymphoblasts
B-ALL markers**
- PAX5, CD 10, 19, 22 (higher numbers)
- loss of function mutations via t(12;21) involving genes ETV6 and RUNX1
- contain tDt
T-ALL markers **
- CD 1,2,5,7
- gain of function mutations in NOTCH1
- contain tDt
chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL)
- most common leukemia of adults
- CLL if mature cell count is high in peripheral blood, lymphoma if count is low
- usually proliferation of naive B cells –> won’t make mature Igs
- growth confined to proliferation centers
- translocations rare
- usually asymptomatic in patients
- more mutations can lead to diffuse large B cell lymphoma aka Richter syndrome**
- lymph nodes effaced by small lymphocytes –> won’t see follicles
- infiltrate spleen, portal tracts, marrow interstitium
- SMUDGE cells***
CLL/SLL markers
- CD5**, 19, 20, 23
- smudge cells on blood smear**
follicular lymphoma
- most common indolent NHL
- translocations of t(14;18) –> BCL-2 over expression** –> no apoptosis
- more mutations –> can progress to diffuse large B cell lymphoma
- infiltrates spleen and marrow paratrabeculae
- contain centrocytes and centroblasts
follicular lymphoma markers**
- CD 10,19,20
- BCL-2 positive**
- CD5 negative, unlike mantle cell lymphoma
diffuse large B cell lymphoma (DLBCL)
- most common form of NHL**
- mutation in t(14;18) is rare –> BCL-2 over expression
- mutation in BLC6** (transcription repressor for normal germinal centers)
- aggressive, enlarged lymph node or extra nodal mass**
- enlarge spleen - risk of rupture
- subtypes: 1. Immunodeficiency-associated large B-cell lymphoma in severe T-cell immunodeficiency 2. Primary effusion lymphoma
DLBCL markers**
-CD 10, 19, 20, and BCL6**
burkitt lymphoma
- fastest growing human tumor**
- very aggressive, responds well to chemo
- african (endemic) –> mandible mass**
- sporadic (nonendemic) –> ileocecum or peritoneum mass**
- not in bone marrow
- translocations in MYC gene (chromosome 8) to Ig heavy chain t(8;14)**–> increase MYC expression (cell growth)
- all endemic burkitt lymphoma latently infected with EBV***
Burkitt lymphoma markers**
- IgM, CD10, 19, 20, BLC6*
- usually fails to express BCL6
- many mitoses and macrophages forming “starry sky”***
plasma cell neoplasms
- B-cell proliferations with neoplastic plasma cells that secrete monoclonal Ig or Ig fragment (marker for tumors)
- multiple myeloma most common and deadly**
multiple myeloma**
- most common primary malignancy of bone**
- plasma cell neoplasm with lytic bone lesions, hypercalcemia, renal failure, and acquired immune abnormalities
- destructive plasma cell tumors (plasmacytomas)
- high serum IL-6 (growth factor) –> stimulates plasma cell growth and Ig production
- translocations of IgH, cyclin D1,D3**
- deletions of chromosome 17p (TP53 tumor suppressor)*
- expansion of plasma cells, crowding out other cells –> cytopenias
clinical symptoms of multiple myeloma**
- bone pain with hypercalcemia –> plasma cells activate RANK on osteoclasts –> bone destruction –> “punched out/lytic skull lesions”, hypercalcemia, risk for fratcture
- elevated serum protein - plasma cells tumors produce Ig –> M spike** due to monoclonal IgG and IgA
- increased risk of infection - monoclonal antibody lacks antigen diversity –> produce exact same antibody (lost diversity)
- rouleaux formation - increasing serum protein decreases charge b/w RBCs
- primary AL amyloidosis - overproduce light chain –> free light chain in serum & tissue deposits –> develop amyloidosis
- light chain –> blood –> amyloidosis
- light chain –> urine –> Bence Jones protein
- light chain –> kidney –> myeloma kidney - proteinuria - light chain excreted in urine as Bence Jones protein and in kidney tubules causing renal failure
waldenstrom maroglobulinemia
- B cell lymphoma that produces monoclonal IgM
- high IgM, hyperviscosity of blood, and associated with lymphoplasmacytic lymphoma
Monoclonal gammopathy of undetermined significance (MGUS)
- M components (spike), common in elderly, may transform to symptomatic MGUS
- can develop into multiple myeloma**
multiple myeloma markers**
- CD 138, often CD56 POS**
- reactive plasmacytosis or MGUS is CD56 NEG**
lymphoplasmacytic lymphoma
- neoplasm of small lymphocytes, plasma cells, and plasmacytoid lymphocytes
- unlike MM, bone destruction does not occur with secretion of light chains**
- mutations in MYD88, which activated NFkB**
- IgM producing tumor** –> hyperviscosity, visual problems, bleeding, and hemolysis
- alleviated by plasmapheresis